These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

510 related items for PubMed ID: 28427541

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Long-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: Results of a randomized 1-year trial in patients with COPD.
    Donohue JF, Soong W, Wu X, Shrestha P, Lei A.
    Respir Med; 2016 Jul; 116():41-8. PubMed ID: 27296819
    [Abstract] [Full Text] [Related]

  • 45. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial.
    Vestbo J, Papi A, Corradi M, Blazhko V, Montagna I, Francisco C, Cohuet G, Vezzoli S, Scuri M, Singh D.
    Lancet; 2017 May 13; 389(10082):1919-1929. PubMed ID: 28385353
    [Abstract] [Full Text] [Related]

  • 46. Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease.
    Rennard S, Fogarty C, Reisner C, Fernandez C, Fischer T, Golden M, Rose ES, Darken P, Tardie G, Orevillo C.
    BMC Pulm Med; 2014 Jul 16; 14():118. PubMed ID: 25027304
    [Abstract] [Full Text] [Related]

  • 47. Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study.
    Chen Q, Hu C, Yu H, Shen K, Assam PN, Gillen M, Liu Y, Dorinsky P.
    Clin Ther; 2019 May 16; 41(5):897-909.e1. PubMed ID: 30982547
    [Abstract] [Full Text] [Related]

  • 48. A randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease.
    D'Urzo A, Rennard S, Kerwin E, Donohue JF, Lei A, Molins E, Leselbaum A.
    Respir Med; 2017 Apr 16; 125():39-48. PubMed ID: 28340861
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. A randomized controlled trial of glycopyrrolate administered by metered dose inhaler in patients with uncontrolled asthma despite ICS/LABA treatment.
    Kerwin E, Dorinsky P, Patel M, Rossman K, Reisner C, Maes A, Darken P, Griffis D, Fjällbrant H.
    J Asthma; 2022 Jul 16; 59(7):1420-1432. PubMed ID: 34338132
    [Abstract] [Full Text] [Related]

  • 51. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.
    Buhl R, Gessner C, Schuermann W, Foerster K, Sieder C, Hiltl S, Korn S.
    Thorax; 2015 Apr 16; 70(4):311-9. PubMed ID: 25677679
    [Abstract] [Full Text] [Related]

  • 52. Efficacy and safety of indacaterol in patients with chronic obstructive pulmonary disease aged over 65 years: A pooled analysis.
    Girodet PO, Jasnot JY, Le Gros V, Decuypère L, Cao W, Devouassoux G.
    Respir Med; 2017 Jul 16; 128():92-101. PubMed ID: 28566230
    [Abstract] [Full Text] [Related]

  • 53. Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).
    Mahler DA, Gifford AH, Satti A, Jessop N, Eckert JH, D'Andrea P, Mota F, Banerjee R.
    Respir Med; 2016 Jun 16; 115():39-45. PubMed ID: 27215502
    [Abstract] [Full Text] [Related]

  • 54. Long-term safety of glycopyrrolate/eFlow® CS in moderate-to-very-severe COPD: Results from the Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer (GOLDEN) 5 randomized study.
    Ferguson GT, Goodin T, Tosiello R, Wheeler A, Kerwin E.
    Respir Med; 2017 Nov 16; 132():251-260. PubMed ID: 28919143
    [Abstract] [Full Text] [Related]

  • 55. Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study.
    Ferguson GT, Papi A, Anzueto A, Kerwin EM, Cappelletti C, Duncan EA, Nyberg J, Dorinsky P.
    Eur Respir J; 2018 Sep 16; 52(3):. PubMed ID: 30220648
    [Abstract] [Full Text] [Related]

  • 56. Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study.
    Singh D, Scuri M, Collarini S, Vezzoli S, Mariotti F, Muraro A, Acerbi D.
    Int J Chron Obstruct Pulmon Dis; 2017 Sep 16; 12():2001-2014. PubMed ID: 28744115
    [Abstract] [Full Text] [Related]

  • 57. A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol.
    Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, Trivedi R, St Rose E, Ballal S, McLaren J, Darken P, Reisner C, Dorinsky P.
    Respir Med; 2019 Sep 16; 158():59-66. PubMed ID: 31605923
    [Abstract] [Full Text] [Related]

  • 58. Efficacy, safety, and dose response of glycopyrronium administered by metered dose inhaler using co-suspension delivery technology in subjects with intermittent or mild-to-moderate persistent asthma: A randomized controlled trial.
    Kerwin E, Wachtel A, Sher L, Nyberg J, Darken P, Siddiqui S, Duncan EA, Reisner C, Dorinsky P.
    Respir Med; 2018 Jun 16; 139():39-47. PubMed ID: 29858000
    [Abstract] [Full Text] [Related]

  • 59. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.
    Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, Guasconi A, Montagna I, Vezzoli S, Petruzzelli S, Scuri M, Roche N, Singh D.
    Lancet; 2018 Mar 17; 391(10125):1076-1084. PubMed ID: 29429593
    [Abstract] [Full Text] [Related]

  • 60. Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study.
    LaForce C, Feldman G, Spangenthal S, Eckert JH, Henley M, Patalano F, D'Andrea P.
    Int J Chron Obstruct Pulmon Dis; 2016 Mar 17; 11():1233-43. PubMed ID: 27354782
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.